Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Quarterly Earnings Results

Posted by Amy Steele on May 8th, 2026

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) released its earnings results on Thursday. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.96), Zacks reports. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $3.77 million.

Zealand Pharma A/S Stock Down 1.4%

Shares of ZLDPF traded down $0.76 on Friday, hitting $53.52. The company’s stock had a trading volume of 671 shares, compared to its average volume of 3,938. The firm’s fifty day moving average price is $46.61 and its 200-day moving average price is $62.88. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $83.12. The company has a quick ratio of 23.57, a current ratio of 23.57 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3.83 billion, a price-to-earnings ratio of 3.91 and a beta of 0.87.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, BNP Paribas Exane cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Three research analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Check Out Our Latest Stock Report on ZLDPF

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.